Works by Zahir, Hamim

Results: 27

Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 5, p. 475, doi. 10.1002/cpdd.1240

By:

Zahir, Hamim;
Yin, Ophelia;
Hsu, Ching;
Wagner, Andrew J.;
Jiang, Jason;
Wang, Xiaoning;
Greenberg, Jon;
Shuster, Dale E.;
Kakkar, Tarundeep;
LaCreta, Frank

Publication type:

Article

Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality.

Published in:

Clinical Pharmacology in Drug Development, 2023, v. 12, n. 2, p. 159, doi. 10.1002/cpdd.1186

By:

Zahir, Hamim;
Greenberg, Jonathan;
Hsu, Ching;
Watanabe, Kengo;
Makino, Chie;
He, Ling;
LaCreta, Frank

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects.

Published in:

Clinical Pharmacology in Drug Development, 2018, v. 7, n. 6, p. 597, doi. 10.1002/cpdd.582

By:

Jansen, Mendel;
Mendell, Jeanne;
Currie, Alexander;
Dow, James;
He, Ling;
Merante, Domenico;
Dishy, Victor;
Ishizuka, Hitoshi;
Zahir, Hamim

Publication type:

Article

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study.

Published in:

Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 3, p. 736, doi. 10.1002/cpt.3196

By:

Zou, Peng;
Zahir, Hamim;
Duggal, Anil;
Pandya, Grishma;
Jin, James;
Leil, Tarek A.

Publication type:

Article

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies.

Published in:

Pharmacology Research & Perspectives, 2018, v. 6, n. 5, p. 1, doi. 10.1002/prp2.418

By:

Brown, Karen;
Mendell, Jeanne;
Ohwada, Shoichi;
Hsu, Ching;
He, Ling;
Warren, Vance;
Dishy, Victor;
Zahir, Hamim

Publication type:

Article

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal.

Published in:

Critical Care, 2016, v. 20, p. 1, doi. 10.1186/s13054-016-1422-2

By:

Brown, Karen S.;
Zahir, Hamim;
Grosso, Michael A.;
Lanz, Hans J.;
Mercuri, Michele F.;
Levy, Jerrold H.

Publication type:

Article

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open‐label, drug–drug interaction study.

Published in:

British Journal of Clinical Pharmacology, 2018, v. 84, n. 10, p. 2317, doi. 10.1111/bcp.13674

By:

Tachibana, Masaya;
Yamamura, Naotoshi;
Atiee, George J.;
Hsu, Ching;
Warren, Vance;
He, Ling;
Dishy, Victor;
Zahir, Hamim

Publication type:

Article

Evaluation of the pharmacokinetic drug interaction potential of tivantinib (ARQ 197) using cocktail probes in patients with advanced solid tumours.

Published in:

British Journal of Clinical Pharmacology, 2018, v. 84, n. 1, p. 112, doi. 10.1111/bcp.13424

By:

Tachibana, Masaya;
Papadopoulos, Kyriakos P.;
Strickler, John H.;
Puzanov, Igor;
Gajee, Roohi;
Wang, Yibin;
Zahir, Hamim

Publication type:

Article

Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.

Published in:

British Journal of Clinical Pharmacology, 2016, v. 82, n. 6, p. 1591, doi. 10.1111/bcp.13092

By:

Parasrampuria, Dolly A.;
Mendell, Jeanne;
Shi, Minggao;
Matsushima, Nobuko;
Zahir, Hamim;
Truitt, Kenneth

Publication type:

Article

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor.

Published in:

American Journal of Cardiovascular Drugs, 2013, v. 13, n. 5, p. 331, doi. 10.1007/s40256-013-0029-0

By:

Mendell, Jeanne;
Zahir, Hamim;
Matsushima, Nobuko;
Noveck, Robert;
Lee, Frank;
Chen, Shuquan;
Zhang, George;
Shi, Minggao

Publication type:

Article

Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.

Published in:

Clinical Pharmacokinetics, 2022, v. 61, n. 11, p. 1623, doi. 10.1007/s40262-022-01172-9

By:

Zahir, Hamim;
Greenberg, Jonathan;
Shuster, Dale;
Hsu, Ching;
Watanabe, Kengo;
LaCreta, Frank

Publication type:

Article

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 4, p. 1016, doi. 10.1007/s10637-013-9934-y

By:

Feldman, Darren;
Einhorn, Lawrence;
Quinn, David;
Loriot, Yohann;
Joffe, Johnathan;
Vaughn, David;
Fléchon, Aude;
Hajdenberg, Julio;
Halim, Abdel-Baset;
Zahir, Hamim;
Motzer, Robert

Publication type:

Article

Effect of a Supratherapeutic Dose of Omaveloxolone on the Corrected QT Interval in Healthy Participants: A Randomized, Double‐Blind, Placebo‐ and Active‐Controlled, Three‐Way Crossover Study.

Published in:

CTS: Clinical & Translational Science, 2025, v. 18, n. 2, p. 1, doi. 10.1111/cts.70139

By:

Zahir, Hamim;
Murai, Masako;
Wu, Lucy;
Valentine, Michelle;
Hynes, Scott M.

Publication type:

Article

Phase I studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of DS‐1211, a tissue‐nonspecific alkaline phosphatase inhibitor.

Published in:

CTS: Clinical & Translational Science, 2022, v. 15, n. 4, p. 967, doi. 10.1111/cts.13214

By:

Maruyama, Sonomi;
Visser, Hester;
Ito, Takashi;
Limsakun, Tharin;
Zahir, Hamim;
Ford, Daniel;
Tao, Ben;
Zamora, Cynthia A.;
Stark, Jeffrey G.;
Chou, Hubert S.

Publication type:

Article

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies.

Published in:

Cancer (0008543X), 2012, v. 118, n. 21, p. 5403, doi. 10.1002/cncr.27526

By:

Pishvaian, Michael J.;
Marshall, John L.;
Wagner, Andrew J.;
Hwang, Jimmy J.;
Malik, Shakun;
Cotarla, Ion;
Deeken, John F.;
He, A. Ruth;
Daniel, Hirut;
Halim, Abdel-Baset;
Zahir, Hamim;
Copigneaux, Catherine;
Liu, Kejian;
Beckman, Robert A.;
Demetri, George D.

Publication type:

Article

Open-Label Single-Dose Study to Assess the Effect of Mild and Moderate Hepatic Impairment on the Pharmacokinetics of Mirogabalin.

Published in:

Clinical Drug Investigation, 2018, v. 38, n. 11, p. 1001, doi. 10.1007/s40261-018-0692-7

By:

Duchin, Kenneth;
Senaldi, Giorgio;
Warren, Vance;
Marbury, Thomas;
Lasseter, Kenneth;
Zahir, Hamim

Publication type:

Article

Use of an Exposure-Response Model to Aid Early Drug Development of an Oral Sphingosine 1-Phosphate Receptor Modulator.

Published in:

Journal of Clinical Pharmacology, 2009, v. 49, n. 1, p. 50, doi. 10.1177/0091270008325672

By:

Rohatagi, Shashank;
Zahir, Hamim;
Moberly, James B.;
Truitt, Kenneth E.;
Inaba, Shin-ichi;
Shimozato, Takaichi;
Carrothers, T. J.

Publication type:

Article

Phamacokinetics, Safety, and Tolerability of Teduglutide, a Glucagon-Like Peptide-2 (GLP-2) Analog, Following Multiple Ascending Subcutaneous Administrations in Healthy Subjects.

Published in:

Journal of Clinical Pharmacology, 2008, v. 48, n. 11, p. 1289, doi. 10.1177/0091270008320605

By:

Marier, Jean-Francois;
Beliveau, Martin;
Mouksassi, Mohamad-Samer;
Shaw, Paula;
Cyran, Jane;
Kesavan, Jothi;
Wallens, John;
Zahir, Hamim;
Wells, David;
Caminis, John

Publication type:

Article

Understanding the mechanisms of food effect on omaveloxolone pharmacokinetics through physiologically based biopharmaceutics modeling.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 10, p. 1771, doi. 10.1002/psp4.13221

By:

Pepin, Xavier J. H.;
Hynes, Scott M.;
Zahir, Hamim;
Walker, Deborah;
Semmens, Lois Q.;
Suarez‐Sharp, Sandra

Publication type:

Article

Exposure–response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.

Published in:

CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 11, p. 1422, doi. 10.1002/psp4.12712

By:

Yin, Ophelia;
Zahir, Hamim;
French, Jonathan;
Polhamus, Daniel;
Wang, Xiaoning;
van de Sande, Michiel;
Tap, William D.;
Gelderblom, Hans;
Wagner, Andrew J.;
Healey, John H.;
Greenberg, Jonathan;
Shuster, Dale;
Stacchiotti, Silvia

Publication type:

Article

Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants.

Published in:

Journal of Clinical Pharmacology, 2025, v. 65, n. 6, p. 715, doi. 10.1002/jcph.6189

By:

Zahir, Hamim;
Murai, Masako;
Wu, Lucy;
Valentine, Michelle;
Hynes, Scott

Publication type:

Article

Relative Bioavailability of Omaveloxolone When Capsules Are Sprinkled Over and Mixed in Applesauce Compared With Administration as Intact Omaveloxolone Capsules: A Phase 1, Randomized, Open‐Label, Single‐Dose, Crossover Study in Healthy Adults

Published in:

Journal of Clinical Pharmacology, 2024, v. 64, n. 10, p. 1304, doi. 10.1002/jcph.2482

By:

Hynes, Scott M.;
Goldsberry, Angie;
Henneghan, Patrick D.;
Murai, Masako;
Shinde, Aparna;
Wells, Jason A.;
Wu, Lucy;
Wu, Tony;
Zahir, Hamim;
Khan, Seemi

Publication type:

Article

Effect of Mild and Moderate Hepatic Impairment (Defined by Child–Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.

Published in:

Journal of Clinical Pharmacology, 2022, v. 62, n. 8, p. 992, doi. 10.1002/jcph.2042

By:

Zahir, Hamim;
Greenberg, Jonathan;
Hsu, Ching;
Marbury, Thomas C.;
Lasseter, Kenneth C.;
Xu, Li‐An;
Tap, William D.;
Healey, John H.;
Stacchiotti, Silvia;
LaCreta, Frank

Publication type:

Article

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors.

Published in:

Journal of Clinical Pharmacology, 2021, v. 61, n. 4, p. 480, doi. 10.1002/jcph.1753

By:

Yin, Ophelia;
Wagner, Andrew J.;
Kang, Jia;
Knebel, William;
Zahir, Hamim;
Sande, Michiel;
Tap, William D.;
Gelderblom, Hans;
Healey, John H.;
Shuster, Dale;
Stacchiotti, Silvia

Publication type:

Article

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein.

Published in:

Journal of Clinical Pharmacology, 2021, v. 61, n. 3, p. 298, doi. 10.1002/jcph.1734

By:

Zahir, Hamim;
Kobayashi, Fumiaki;
Zamora, Cynthia;
Gajee, Roohi;
Gordon, Michael S.;
Babiker, Hani M.;
Wang, Qiang;
Greenberg, Jonathan;
Wagner, Andrew J.

Publication type:

Article

Pharmacological Modulation of Peripheral T and B Lymphocytes by a Selective Sphingosine 1-Phosphate Receptor-1 Modulator.

Published in:

Journal of Clinical Pharmacology, 2012, v. 52, n. 7, p. 996, doi. 10.1177/0091270011408728

By:

Moberly, James B.;
Rohatagi, Shashank;
Zahir, Hamim;
Hsu, Ching;
Noveck, Robert J.;
Truitt, Kenneth E.

Publication type:

Article

Metabolism and disposition of [<sup>14</sup>C]tivantinib after oral administration to humans, dogs and rats.

Published in:

Xenobiotica, 2014, v. 44, n. 11, p. 996, doi. 10.3109/00498254.2014.926572

By:

Murai, Takahiro;
Takakusa, Hideo;
Nakai, Daisuke;
Kamiyama, Emi;
Taira, Tomoe;
Kimura, Tomoko;
Jimbo, Takeshi;
Bathala, Mohinder;
Pickersgill, Fraser;
Zahir, Hamim;
Tokui, Taro;
Savage, Ronald E.;
Ashwell, Mark A.;
Izumi, Takashi

Publication type:

Article